228 related articles for article (PubMed ID: 38138301)
1. Poly (ADP-ribose) Polymerase Inhibitors in Patients with Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis of Randomized Controlled Trials.
Chao Z; Wang Z; Li L; Jiang Y; Tang Y; Wang Y; Hao X; Zhang C; Guo X; Yu W; Cheng F; Wang Z
Medicina (Kaunas); 2023 Dec; 59(12):. PubMed ID: 38138301
[No Abstract] [Full Text] [Related]
2. Efficacy of Poly(ADP-ribose) Polymerase Inhibitors by Individual Genes in Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer: A US Food and Drug Administration Pooled Analysis.
Fallah J; Xu J; Weinstock C; Gao X; Heiss BL; Maguire WF; Chang E; Agrawal S; Tang S; Amiri-Kordestani L; Pazdur R; Kluetz PG; Suzman DL
J Clin Oncol; 2024 May; 42(14):1687-1698. PubMed ID: 38484203
[TBL] [Abstract][Full Text] [Related]
3. Poly (ADP-ribose) Polymerase Inhibitors Have Comparable Efficacy with Platinum Chemotherapy in Patients with BRCA-positive Metastatic Castration-resistant Prostate Cancer. A Systematic Review and Meta-analysis.
Fazekas T; Széles ÁD; Teutsch B; Csizmarik A; Vékony B; Kói T; Ács N; Hegyi P; Hadaschik B; Nyirády P; Szarvas T
Eur Urol Oncol; 2024 Jun; 7(3):365-375. PubMed ID: 37722977
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of PARP Inhibitors as Maintenance Therapy for Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis of Randomized Controlled Trials.
Niazi M; Jahangir A; Sahra S; Sattar S; Asti D; Bershadskiy A
Oncology (Williston Park); 2021 Nov; 35(11):708-715. PubMed ID: 35088974
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of PARP inhibitors in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis of clinical trials.
Iannantuono GM; Chandran E; Floudas CS; Choo-Wosoba H; Butera G; Roselli M; Gulley JL; Karzai F
Cancer Treat Rev; 2023 Nov; 120():102623. PubMed ID: 37716332
[TBL] [Abstract][Full Text] [Related]
6. Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.
Tattersall A; Ryan N; Wiggans AJ; Rogozińska E; Morrison J
Cochrane Database Syst Rev; 2022 Feb; 2(2):CD007929. PubMed ID: 35170751
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of poly (ADP-ribose) polymerase inhibitors therapy for
Zhang M; Yu X; Wang J; Li Y; Cao L
J Cancer Res Ther; 2021 Dec; 17(7):1672-1678. PubMed ID: 35381738
[TBL] [Abstract][Full Text] [Related]
8. Combining PARP Inhibitors and Androgen Receptor Signalling Inhibitors in Metastatic Prostate Cancer: A Quantitative Synthesis and Meta-analysis.
Messina C; Giunta EF; Signori A; Rebuzzi SE; Banna GL; Maniam A; Buti S; Cattrini C; Fornarini G; Bauckneht M; Greystoke A; Plummer R; Oing C; Rescigno P
Eur Urol Oncol; 2024 Apr; 7(2):179-188. PubMed ID: 37574390
[TBL] [Abstract][Full Text] [Related]
9. PARP Inhibitors in Metastatic Prostate Cancer: A Comprehensive Systematic Review and Meta-analysis of Existing Evidence.
Ditonno F; Bianchi A; Malandra S; Porcaro AB; Fantinel E; Negrelli R; Ferro M; Milella M; Brunelli M; Autorino R; Cerruto MA; Veccia A; Antonelli A
Clin Genitourin Cancer; 2024 Apr; 22(2):402-412.e17. PubMed ID: 38281877
[TBL] [Abstract][Full Text] [Related]
10. Poly(adenosine diphosphate-ribose) polymerase inhibitor combinations in first-line metastatic castrate-resistant prostate cancer setting: a systematic review and meta-analysis.
Sayyid RK; Klaassen Z; Berlin A; Roy S; Brandão LR; Bernardino R; Chavarriaga J; Jiang DM; Spratt DE; Fleshner NE; Wallis CJD
BJU Int; 2023 Dec; 132(6):619-630. PubMed ID: 37461140
[TBL] [Abstract][Full Text] [Related]
11. Hematological Toxicity of PARP Inhibitors in Metastatic Prostate Cancer Patients with Mutations of BRCA or HRR Genes: A Systematic Review and Safety Meta-analysis.
Maiorano BA; De Giorgi U; Verzoni E; Maiello E; Procopio G; Conteduca V; Di Maio M;
Target Oncol; 2024 Jan; 19(1):1-11. PubMed ID: 37993604
[TBL] [Abstract][Full Text] [Related]
12. Combining Novel Hormonal Therapies with a Poly (ADP-Ribose) Polymerase Inhibitor for Metastatic Castration-Resistant Prostate Cancer: Emerging Evidence.
Yang J; Xiong X; Zheng W; Liao X; Xu H; Yang L; Wei Q
Curr Oncol; 2023 Dec; 30(12):10311-10324. PubMed ID: 38132385
[TBL] [Abstract][Full Text] [Related]
13. Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial.
Clarke N; Wiechno P; Alekseev B; Sala N; Jones R; Kocak I; Chiuri VE; Jassem J; Fléchon A; Redfern C; Goessl C; Burgents J; Kozarski R; Hodgson D; Learoyd M; Saad F
Lancet Oncol; 2018 Jul; 19(7):975-986. PubMed ID: 29880291
[TBL] [Abstract][Full Text] [Related]
14. Abiraterone for treatment of metastatic castration-resistant prostate cancer: a systematic review and meta-analysis.
Zhou ZR; Liu SX; Zhang TS; Xia J; Li B
Asian Pac J Cancer Prev; 2014; 15(3):1313-20. PubMed ID: 24606458
[TBL] [Abstract][Full Text] [Related]
15. Comparative efficacy, safety, and acceptability of single-agent poly (ADP-ribose) polymerase (PARP) inhibitors in
Wang J; Zhang Y; Yuan L; Ren L; Zhang Y; Qi X
Aging (Albany NY); 2020 Nov; 13(1):450-459. PubMed ID: 33257598
[TBL] [Abstract][Full Text] [Related]
16. Comparative efficacy of olaparib in combination with or without novel antiandrogens for treating metastatic castration-resistant prostate cancer.
Chen X; Pan Y; Wang Q; Ren C; Li M; Hao X; Xie L; Liu X
Front Endocrinol (Lausanne); 2023; 14():1225033. PubMed ID: 38027160
[TBL] [Abstract][Full Text] [Related]
17. Poly-ADP ribose polymerase inhibitor and androgen receptor signaling inhibitor for all comers for first-line treatment of metastatic castration-resistant prostate cancer: is gene sequencing out?
Higano CS; Cheng HH
Curr Opin Urol; 2023 Sep; 33(5):396-403. PubMed ID: 37497748
[TBL] [Abstract][Full Text] [Related]
18. A Meta-Analysis of Randomized Clinical Trials Assessing the Efficacy of PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer.
Alameddine Z; Niazi MRK; Rajavel A; Behgal J; Keesari PR; Araji G; Mustafa A; Wei C; Jahangir A; Terjanian TO
Curr Oncol; 2023 Oct; 30(10):9262-9275. PubMed ID: 37887569
[TBL] [Abstract][Full Text] [Related]
19. Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial.
Agarwal N; Azad AA; Carles J; Fay AP; Matsubara N; Heinrich D; Szczylik C; De Giorgi U; Young Joung J; Fong PCC; Voog E; Jones RJ; Shore ND; Dunshee C; Zschäbitz S; Oldenburg J; Lin X; Healy CG; Di Santo N; Zohren F; Fizazi K
Lancet; 2023 Jul; 402(10398):291-303. PubMed ID: 37285865
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of second-line agents for treatment of metastatic castration-resistant prostate cancer progressing after docetaxel. A systematic review and meta-analysis.
Perletti G; Monti E; Marras E; Cleves A; Magri V; Trinchieri A; Rennie PS
Arch Ital Urol Androl; 2015 Jul; 87(2):121-9. PubMed ID: 26150028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
